Price
CHART BY
Frequently asked questions
What is UCB Unsponsored Belgium ADR's market capitalization?
The market capitalization of UCB Unsponsored Belgium ADR is €53.43B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is UCB Unsponsored Belgium ADR's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for UCB Unsponsored Belgium ADR is 30.35. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for UCB Unsponsored Belgium ADR?
UCB Unsponsored Belgium ADR's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $4.686. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for UCB Unsponsored Belgium ADR's stock?
Currently, 20 analysts cover UCB Unsponsored Belgium ADR's stock, with a consensus target price of €173.37. Analyst ratings provide insights into the stock's expected performance.
What is UCB Unsponsored Belgium ADR's revenue over the trailing twelve months?
Over the trailing twelve months, UCB Unsponsored Belgium ADR reported a revenue of €8.77B.
What is the EBITDA for UCB Unsponsored Belgium ADR?
UCB Unsponsored Belgium ADR's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is €3.00B. EBITDA measures the company's overall financial performance.
What is the free cash flow of UCB Unsponsored Belgium ADR?
UCB Unsponsored Belgium ADR has a free cash flow of €2.19B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does UCB Unsponsored Belgium ADR have, and what sector and industry does it belong to?
UCB Unsponsored Belgium ADR employs approximately 10,117 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
Financials
- Market Cap
- €53.43B
- EPS (TTM)
- $4.686
- P/E ratio (TTM)
- 30.35
- Revenue (TTM)
- €8.77B
- EBITDA (TTM)
- €3.00B
- Free Cashflow (TTM)
- €2.19B
Pricing
- 1D span
- $139.15$141.71
- 52W span
- $85.99$169.54
Analyst Ratings
The price target is €173.37 and the stock is covered by 20 analysts.
Buy
17
Hold
2
Sell
1
Information
UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
- Employees
- 10,117
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- UCBJY
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet